CFOMr. Thomas R. Mika was appointed as Chief Financial Officer of the Company., effective November 2, 2016. Mika currently serves as the Chairman of the Board of Rennova Health, the successor company to CollabRx and its predecessor, Tegal Corporationrationration, a semiconductor capital equipment company. Since 2005, he was the President and CEO, and at times the Acting Chief Financial Officer of CollabRx and Tegal, retaining those positions following its merger with Rennova Health in November 2015. Previously, Mika cofounded IMTEC, a boutique investment and consulting firm, serving clients in the U.S., Europe and Japan over a period of 20 years, taking on the role of CEO in several ventures. Earlier in his career, Mika was a managing consultant with Cresap, McCormick Paget and a policy analyst for the National Science Foundation. He holds a BS in Microbiology from the University of Illinois at UrbanaChampaign and a MBA from the Harvard Graduate School of Business.
Age: 63 CFO Since 2016 MBA